8-K/A: AtriCure Q3 Revenue Jumps 15.8%; 2025 Outlook Raised

AtriCure, Inc. reported strong third quarter 2025 financial results with worldwide revenue increasing 15.8% year-over-year and raised its full-year financial outlook.

Summary

• Worldwide revenue for the third quarter 2025 was $134.3 million, an increase of 15.8% year-over-year (15.1% on a constant currency basis).
• Net loss for the third quarter 2025 improved to $0.3 million, a $7.6 million improvement compared to the third quarter 2024.
• Adjusted EBITDA for the third quarter 2025 increased by $9.9 million year-over-year to $17.8 million.
• Generated $30.1 million in cash during the third quarter and $25.1 million year-to-date.
• Gross margin for the third quarter 2025 was 75.5%, an increase of 59 basis points from the third quarter 2024, reflecting a favorable product mix.
• Income from operations for the third quarter 2025 was $0.2 million, compared to a loss from operations of $7.4 million for the third quarter 2024.
• Basic and diluted net loss per share was $0.01 for the third quarter 2025, a significant improvement from $0.17 for the third quarter 2024.
• Full year 2025 revenue is now projected to be approximately $532 million to $534 million.
• Full year 2025 Adjusted EBITDA is now expected to be approximately $55 million to $57 million.
• Full year 2025 adjusted loss per share is expected to be in the range of $0.23 to $0.26.
• Management continues to expect cash flow generation for the full year 2025.

Sentiment

Score: 8

Explanation: The company reported strong revenue growth, significant improvements in net loss and Adjusted EBITDA, and raised its full-year financial outlook, indicating robust operational execution and market traction for its products. While still reporting a net loss, the substantial year-over-year improvement and positive cash generation are strong indicators.

Positives

• Strong worldwide revenue growth of 15.8% year-over-year to $134.3 million in Q3 2025, indicating continued product adoption.
• Significant improvement in net loss, reducing to $0.3 million in Q3 2025 from $7.853 million in Q3 2024.
• Adjusted EBITDA increased substantially by $9.9 million year-over-year to $17.8 million in Q3 2025, demonstrating improved operational efficiency.
• Generated strong cash flow of $30.1 million in Q3 2025 and $25.1 million year-to-date.
• Gross margin improved by 59 basis points to 75.5% in Q3 2025 due to a favorable product mix.
• Transitioned from an operating loss of $7.4 million in Q3 2024 to an operating income of $0.2 million in Q3 2025.
• U.S. revenue grew 14.5% to $109.3 million, driven by key product lines like AtriClip FLEXMini, EnCompass clamp, and cryoSPHERE MAX probe.
• International revenue increased 22.0% to $25.0 million, showing broad growth across franchises and regions.
• Raised full-year 2025 financial outlook for revenue and Adjusted EBITDA, signaling increased confidence in future performance.

Negatives

• Despite significant improvements, the company still reported a net loss of $0.3 million for the third quarter 2025.
• The company continues to project an adjusted loss per share for the full year 2025, ranging from $0.23 to $0.26.

Risks

• Estimates of the market for products may be inaccurate.
• The rate and degree of market acceptance of products may be lower than anticipated.
• Negative clinical data could impact product adoption and sales.
• Competition from existing and new products and procedures, including the development of drugs or catheter-based technologies, could reduce market share.
• Reliance on independent distributors to sell products poses a risk to sales channels.
• Inventory-related charges could negatively impact profitability.
• Delays in obtaining and maintaining regulatory clearances and approvals for products.
• Impacts of rising healthcare costs on product demand and pricing.
• Ability to comply with extensive FDA regulations.
• Timing of and ability to obtain third-party payor reimbursement for procedures utilizing products.
• Unfavorable publicity could damage brand reputation and sales.
• Potential impact of any acquisitions, mergers, dispositions, joint ventures, or investments.
• Disruptions to manufacturing operations.
• Impact of tariffs or other restrictive trade measures.
• Failure to properly manage growth.
• Disruptions of critical information systems or material breaches in the security of systems.
• Ability to manage intellectual property rights to provide meaningful protection.
• Fluctuation of quarterly financial results.
• Fluctuations in foreign currency exchange rates.
• Reliance on third-party manufacturers and suppliers.
• Litigation, administrative, or other proceedings.

Future Outlook

Management raised its full year 2025 revenue guidance to approximately $532 million to $534 million and Adjusted EBITDA to approximately $55 million to $57 million. The full year 2025 adjusted loss per share is expected to be in the range of $0.23 to $0.26. The company continues to anticipate generating cash flow for the full year 2025.

Management Comments

• "Our third quarter results demonstrate strong execution and patient focus across the business."
• "We are seeing continued positive traction with our most recent product launches, including our AtriClip platform and cryoSPHERE devices, coupled with durable momentum from expanding adoption of our EnCompass clamp."
• "As we invest in product innovation and clinical science to build catalysts for the future, we are determined to drive exceptional financial performance, underscored by continued growth and increasing profitability."

Industry Context

AtriCure operates in the medical device industry, specifically focusing on treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management. The reported growth in revenue and improved profitability suggest strong performance within its niche, driven by the adoption of innovative products like the AtriClip platform, cryoSPHERE devices, and EnCompass clamp. The market for Afib treatments is significant, affecting over 59 million people worldwide, indicating a substantial addressable market for AtriCure's specialized technologies.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased revenue, improved profitability metrics (Adjusted EBITDA, reduced net loss), and raised full-year guidance, potentially leading to increased share value.
• Employees: Continued investment in product innovation and clinical science suggests ongoing stability and potential growth opportunities.
• Customers (Physicians/Hospitals): Continued adoption of products like AtriClip FLEXMini, EnCompass clamp, and cryoSPHERE MAX probe indicates satisfaction and clinical utility.
• Suppliers: Increased product demand (implied by revenue growth) could lead to increased business for suppliers.

Next Steps

• Hold a conference call on October 29, 2025, at 4:30 p.m. Eastern Time to discuss the third quarter 2025 financial results.
• Continue investing in product innovation and clinical science to build catalysts for the future.
• Drive exceptional financial performance, underscored by continued growth and increasing profitability.

Key Dates

Recommendation

The company demonstrated strong operational execution in Q3 2025 with significant revenue growth, substantial improvement in profitability metrics like Adjusted EBITDA and net loss, and robust cash generation. The decision to raise full-year guidance for both revenue and Adjusted EBITDA signals management's confidence in continued positive momentum. The strong adoption of key product lines further reinforces the company's market position and growth trajectory, making it an attractive investment.

Keywords

AtriCure, ATRC, Financial Results, Q3 2025, Revenue, Adjusted EBITDA, Net Loss, Atrial Fibrillation, Afib, Left Atrial Appendage, LAA Management, Post-operative Pain Management, Medical Devices, Surgical Treatments, Cardiac Surgery, Outlook, Guidance